Pediatric Palliative Care, Dana-Farber / Boston Children's Cancer and Blood Disorders Center, Boston, MA, United States of America.
Center for Research and Implementation in Palliative Care, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.
PLoS One. 2022 Nov 8;17(11):e0277212. doi: 10.1371/journal.pone.0277212. eCollection 2022.
The Pediatric Quality of Life and Evaluation of Symptoms Technology Response to Pediatric Oncology Symptom Experience (PQ-Response) intervention aims to integrate specialized pediatric palliative care into the routine care of children, adolescents, and young adults (AYAs) with advanced cancer.
To evaluate whether PQ-Response, compared to usual care, improves patient's health related quality of life (HRQoL) and symptom burden (aim 1), parent psychological distress and symptom-related stress (aim 2), and family and symptom treatment activation (aim 3).
Multisite, randomized (1:1), controlled, un-blinded, effectiveness trial comparing PediQUEST Response (intervention) vs usual cancer care (control).
Five US large, tertiary level pediatric cancer centers.
Children (≥2 years old)/AYAs who receive care at any of the participating sites because of advanced cancer or any progressive/recurrent solid or brain tumor and are palliative care "naïve." Target: 200 enrolled patient-parent dyads (minimum goal: 136 dyads randomized, N = 68/arm).
PediQUEST Response: combines patient-mediated activation (weekly feedback of patient- and parent-reported symptoms and HRQoL to families and providers using the PediQUEST web system) with integration of the palliative care team. Usual Cancer Care: participants receive usual care, which can include palliative care consultation, and use PediQUEST web to answer surveys, with no feedback.
Following enrollment, patients (if ≥5 years) and one parent receive weekly PediQUEST-Surveys assessing HRQoL (Pediatric Quality of Life Inventory 4.0) and symptom burden (PediQUEST-Memorial Symptom Assessment Scale). After a 2-week run-in period, dyads who answer ≥2 PediQUEST surveys per participant (responders), are randomized (concealed allocation) and followed up for 16-weeks. Parents answer six additional surveys (parent outcomes).
Primary: mean patient HRQoL score over 16-weeks as reported by a) the parent; and b) the patient if ≥5 years-old. Secondary: patient's symptom burden; parent's anxiety, depressive symptoms, symptom-related stress; family activation; and symptom treatment activation.
ClinicalTrials.gov (NCT03408314) 1/24/18. https://clinicaltrials.gov/ct2/show/NCT03408314.
儿科生活质量和症状评估技术对儿科肿瘤症状体验的反应(PQ-Response)干预旨在将专门的儿科姑息治疗纳入患有晚期癌症的儿童、青少年和年轻人(AYAs)的常规护理中。
评估 PQ-Response 是否比常规护理更能提高患者的健康相关生活质量(HRQoL)和症状负担(目标 1)、父母的心理困扰和与症状相关的压力(目标 2)以及家庭和症状治疗的激活(目标 3)。
多站点、随机(1:1)、对照、非盲、有效性试验,比较 PediQUEST Response(干预)与常规癌症护理(对照)。
美国五家大型三级儿科癌症中心。
患有晚期癌症或任何进行性/复发性实体瘤或脑肿瘤且接受姑息治疗的儿童(≥2 岁)/AYAs 是“姑息治疗新手”。目标:200 名入组的患者-父母对子(最低目标:136 对子随机分组,N=68/组)。
PediQUEST Response:结合患者介导的激活(每周向家庭和提供者反馈患者和家长报告的症状和 HRQoL,使用 PediQUEST 网络系统)和姑息治疗团队的整合。常规癌症护理:参与者接受常规护理,包括姑息治疗咨询,并使用 PediQUEST 网络回答调查,没有反馈。
入组后,患者(如果≥5 岁)和一位家长每周接受 PediQUEST-Surveys 评估 HRQoL(儿科生活质量清单 4.0)和症状负担(PediQUEST-Memorial 症状评估量表)。经过两周的适应期,对每例参与者至少回答 2 次 PediQUEST 调查的患者-家长对子(应答者)进行随机分组(隐蔽分配),并随访 16 周。家长还需额外回答 6 份调查问卷(家长结果)。
主要:由 a)家长和 b)如果患者≥5 岁,则由患者报告的 16 周内患者 HRQoL 评分的平均值。次要:患者的症状负担;家长的焦虑、抑郁症状、与症状相关的压力;家庭激活;以及症状治疗的激活。
ClinicalTrials.gov(NCT03408314)1 月 24 日 2018 年。https://clinicaltrials.gov/ct2/show/NCT03408314。